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Background: β-Lapachone (β-LAP) is a natural naphthoquinone compound isolated from the lapacho tree
(Tabebuia sp.), and it has been used for treatment of rheumatoid arthritis, infection, and cancer. In the present
study, we investigated whether β-LAP has anti-inflammatory effects under in vitro and in vivo neuroinflammatory
conditions.
Methods: The effects of β-LAP on the expression of inducible nitric oxide synthase (iNOS), cytokines, and matrix
metalloproteinases (MMPs) were examined in lipopolysaccharide (LPS)-stimulated BV2 microglial cells and rat primary
microglia by ELISA, reverse transcription polymerase chain reaction (RT-PCR), and Western blot analysis. Microglial
activation and the expression levels of proinflammatory molecules were measured in the LPS-injected mouse brain
by immunohistochemistry and RT-PCR analysis. The detailed molecular mechanism underlying the anti-inflammatory
effects of β-LAP was analyzed by electrophoretic mobility shift assay, reporter gene assay, Western blot, and RT-PCR
analysis.
Results: β-LAP inhibited the expression of iNOS, proinflammatory cytokines, and MMPs (MMP-3, MMP-8, MMP-9) at
mRNA and protein levels in LPS-stimulated microglia. On the other hand, β-LAP upregulated the expressions of anti-
inflammatory molecules such as IL-10, heme oxygenase-1 (HO-1), and the tissue inhibitor of metalloproteinase-2
(TIMP-2). The anti-inflammatory effect of β-LAP was confirmed in an LPS-induced systemic inflammation mouse
model. Thus, β-LAP inhibited microglial activation and the expressions of iNOS, proinflammatory cytokines, and
MMPs in the LPS-injected mouse brain. Further mechanistic studies revealed that β-LAP exerts anti-inflammatory
effects by inhibiting MAPKs, PI3K/AKT, and NF-κB/AP-1 signaling pathways in LPS-stimulated microglia. β-LAP also
inhibited reactive oxygen species (ROS) production by suppressing the expression and/or phosphorylation of NADPH
oxidase subunit proteins, such as p47phox and gp91phox. The anti-oxidant effects of β-LAP appeared to be related
with the increase of HO-1 and NQO1 via the Nrf2/anti-oxidant response element (ARE) pathway and/or the PKA
pathway.
Conclusions: The strong anti-inflammatory/anti-oxidant effects of β-LAP may provide preventive therapeutic
potential for various neuroinflammatory disorders.
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Microglia are innate immune cells of the central nervous
system that constantly move through the brain paren-
chyma and constitute an immune surveillance system
[1, 2]. Microglia become activated in response to various
stimuli or injury and produce inflammatory mediators
such as nitric oxide (NO), cytokines, and matrix metallo-
proteinases (MMPs). Alternatively, activated microglia
produce anti-inflammatory cytokines and lead to matrix
deposition and wound healing [3, 4]. Thus, the balance be-
tween the inflammatory M1 and the anti-inflammatory
M2 phase of microglial activation is important to maintain
homeostasis in the brain. However, prolonged and unre-
solved inflammatory response leads to destructive, chronic
inflammation (neuroinflammation) that results in neur-
onal cell death and ultimately in the onset of neurodegen-
erative diseases [5, 6]. Therefore, inhibition of exaggerated
inflammatory responses by microglia has been suggested
as an important strategy to develop therapeutic agents for
various neuroinflammatory disorders.
β-Lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-
b]pyran-5,6-dione; β-LAP) is a natural compound which
was originally isolated from the bark of the South American
lapacho tree (Tabebuia avellanedae) [7]. β-LAP has been
reported to have a wide variety of pharmacological
effects including anti-inflammatory, anti-cancer, anti-
bacterial, anti-fungal, anti-platelet, and anti-angiogenic
action [8–10]. In particular, β-LAP exerts anti-
neoplastic effects against various human cancer cell
lines, and it is now being used in clinical trials for the
treatment of various forms of cancer [11–13]. β-LAP
has topoisomerase inhibitory activity and elevates
NQO1 levels, leading to a futile redox cycle and apop-
tosis of cancer cells [11, 14]. A recent study reports that
β-LAP attenuates cisplatin-mediated nephrotoxicity by
increasing NAD+ levels with elevated tumoricidal
effects of cisplatin [15]. Several studies have reported
anti-inflammatory effects of β-LAP. β-LAP suppresses
inflammatory responses in activated macrophages and
protects from lung edema and high mortality in septic
mice [16]. β-LAP alleviates carrageenan-induced rat
paw edema by suppressing neutrophil migration and
cytokine production [17]. In addition, β-LAP induces
anti-inflammatory heme oxygenase-1 (HO-1) via
AMPK activation in RAW264.7 macrophages and
endothelial cells [18, 19]. A previous study has shown
anti-inflammatory effects of β-LAP in activated micro-
glia [20]. It was demonstrated that β-LAP inhibits indu-
cible nitric oxide synthase (iNOS) and cytokine
expressions in lipopolysaccharide (LPS)-stimulated BV2
cells. However, the in vivo effects of β-LAP and the de-
tailed molecular mechanism underlying the anti-
inflammatory effects of β-LAP have not been fully
elucidated.Therefore, in the present study, we examined the
anti-inflammatory effects of β-LAP under both in vitro
and in vivo neuroinflammatory conditions and ana-
lyzed, in detail, the molecular mechanism. In particular,
we investigated the effects of β-LAP on the gene
expression and activity of MMPs, because our group
recently demonstrated the proinflammatory role of
MMPs in activated microglia [21–23]. Through this
study, we report for the first time that β-LAP inhibits
microglial activation and expression of iNOS, cytokines,
and several MMPs in the LPS-injected mouse brain.
Furthermore, we demonstrated that multiple signaling
pathways are involved in the anti-inflammatory mech-
anism of β-LAP in activated microglia.Materials and methods
Reagents and antibodies
All reagents for cell culture were purchased from Gibco
BRL (Grand Island, NY, USA). β-Lapachone and LPS
(Escherichia coli serotype 055:B5) were obtained from
Sigma–Aldrich (St. Louis, MO, USA). All reagents and
enzymes for reverse transcription polymerase chain re-
action (RT-PCR) and oligonucleotides for electrophor-
etic mobility shift assay (EMSA) were purchased from
Promega (Madison, WI, USA). Antibodies against phos-
pho-/total forms of MAPKs, CREB, β-actin, MMPs
(MMP-3, MMP-8, MMP-9), and tissue inhibitor of
metalloproteinase-2 (TIMP-2) were supplied by Cell
Signaling Technology (Beverley, CA, USA), Abcam
(Cambridge, UK), or Chemicon (Temecula, CA, USA).
Antibodies against HO-1, NQO1, and Iba1 were pur-
chased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) or Novus (Littleton, CO, USA). The antibody
for phospho-p47phox (Ser370) was purchased from
Assay Biotechnology Company Inc. (Sunnyvale, CA,
USA). All other chemicals were obtained from Sigma–
Aldrich, unless otherwise stated.Microglial cell cultures
The immortalized mouse BV2 microglial cell line [24]
was grown and maintained in Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 10 % heat-
inactivated fetal bovine serum, streptomycin (10 μg/ml),
and penicillin (10 U/ml) at 37 °C under 5 % CO2. Pri-
mary microglial cells were cultured from the cerebral
cortices of 1- to 2-day-old Sprague Dawley rat pups as
described previously [21]. The purity of microglial cul-
tures was >95 %, as confirmed by Western blot and im-
munocytochemistry analyses using an antibody specific
to ionized calcium-binding adapter protein-1 (IBA-1)
staining (data not shown).
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Cells (1 × 105 cells per well in a 48-well plate) were pre-
treated with β-LAP for 1 h and further stimulated with
LPS (100 ng/ml) for 16 h. Concentrations of TNF-α, IL-1β,
IL-6, and IL-10 in conditioned medium (CM) were mea-
sured by ELISA using monoclonal antibodies and proce-
dures recommended by the supplier (PharMingen, San
Diego, CA). Accumulated nitrite in CM and intracellular
accumulation of reactive oxygen species (ROS) were mea-
sured using Griess reagent (Promega) and H2DCF-DA
(Invitrogen, La Jolla, USA), respectively, as previously de-
scribed [25].
Assays for MMP-3, MMP-8, and MMP-9 activity
BV2 cells were stimulated with LPS in the presence or
absence of β-LAP for 24 h, and the supernatants were
collected to measure MMP activity using the SensoLyte®
520 MMP assay system (AnaSpec, San Jose, CA, USA).
MMP activity measurements were performed by con-
tinuous detection of peptide cleavage using a fluores-
cence plate reader (Molecular Devices, Sunnyvale, CA,
USA). MMP activity units were expressed as a change in
the fluorescence intensity at an excitation wavelength of
490 nm and an emission wavelength of 520 nm.
LPS-induced inflammation and administration of β-LAP
C57BL/6 mice (10–11 weeks old) were purchased from
the Orient Co., Ltd. (Seoul, Korea). All animal experi-
ments were approved by the Institutional Animal Care
and Use Committee at the School of Medicine, Ewha
Womans University. All efforts were made to minimize
animal suffering, to reduce the number of animals used,
and to utilize alternatives to in vivo techniques, if avail-
able. Systemic inflammation was induced by LPS adminis-
tration (5 mg/kg, i.p.) to male C57BL/6 mice as previously
described [26]. β-LAP (10 mg/kg, i.p.), dissolved in vehicle
solution (1 % DMSO and normal saline), was given daily
for 4 days before the LPS treatment. Samples were ob-
tained 3 or 6 h after LPS treatment.
Immunohistochemistry
Three hours after LPS treatment, the animals were anes-
thetized with sodium pentobarbital (120 mg/kg i.p.) and
perfused transcardially with normal saline containing
heparin (5 U/ml), followed by 4 % paraformaldehyde
(PFA) in 0.1 M sodium phosphate buffer (PBS), pH 7.2.
The brains were removed and incubated overnight in
fixatives and stored in a 30 % sucrose solution. Serial
coronal brain sections of regions containing the hippo-
campus (20 μm thick, at 600-μm intervals) were col-
lected using a cryostat. Brain sections were incubated in
PBS containing 0.1 % Triton X-100, 5 % normal serum,
and 1 % bovine serum albumin for 1 h, and thensubsequently incubated with primary antibody. On the
next day, sections were incubated in a 1:200 dilution of
Alexa Fluor 488-labeled donkey anti-rabbit secondary
antibody or Alexa Fluor 594-labeled chicken anti-goat
antibody (Molecular Probes Inc., Eugene, OR, USA) for
60 min at room temperature, and then washed with
0.05 % Tween 20 in PBS three times, 5 min each. Sec-
tions were then stained with a 0.5-μg/ml DAPI staining
solution for 20 min at room temperature and washed.
The sections were mounted with Vectashield mounting
medium (Vector Laboratories, Burlingame, CA, USA),
and fluorescence microcopy images were obtained
using confocal microscopy (TSC-SP, Leica, Heidelberg,
Germany). Iba1-, MMP-3-, MMP-8-, and MMP-9-
positive cells were quantified using the Metamorph
program (Carl Zeiss, Jena, Germany). Two serial brain
sections from each animal were used for further ana-
lysis, and quantification of Iba1-, MMP-3-, MMP-8-,
and MMP-9-positive cells was performed in three dif-
ferent areas (500 μm2 in size) in the lateral cortex and
dentate gyrus of the right hemisphere per brain section.
The mean cell number from six 500-μm2 areas per ani-
mal was calculated.RT-PCR
Total RNA (1 μg) isolated from BV2 or primary micro-
glial cells (4.5 × 105 cells on a 6-cm dish), or from the
brain tissue of LPS-injected mice, was reverse tran-
scribed, and synthesized cDNA was used as a template
for PCR. RT-PCR was performed on a T100 Thermal
Cycler (Bio-Rad) with GoTaq polymerase (Promega).
The primer sets shown in Table 1 were used to detect
specific PCR products, and their values were calculated
as fold change relative to control after normalization to
the GAPDH gene.Western blot analysis
Proteins isolated from total cell lysates, and from CM,
were separated by SDS-PAGE, transferred to nitrocellu-
lose membranes, and incubated with primary antibodies
against MMP-3, MMP-8, and MMP-9; TIMP-2 (1:1000);
the phospho- or total form of MAP kinases or CREB;
HO-1; NQO1 (1:1000); or p-p47phox [anti-phospho-
(Ser345)-p47phox Ab] (1:1000, Assay Biotechnology).
After thorough washing with Tris-buffered saline with
Tween 20 (TBST), horseradish peroxidase-conjugated sec-
ondary antibodies (1:2000 dilution in TBST; New England
Biolabs, Beverly, MA, USA) were applied, and the blots
were developed using an enhanced chemiluminescence
detection kit (Pierce Biotechnology, Rockford, IL, USA).
To detect secreted MMPs, MMP proteins in the condi-
tioned media were enriched using an Amicon® centrifugal
filter (Millipore Corp., Billerica, MA, USA).
Table 1 Primers used in RT-PCR reactions
Species Gene Forward primer (5′→ 3′) Reverse primer (5′→ 3′) Size (bp)
Mouse TNF-α CCTATGTCTCAGCCTCTTCT CCTGGTATGAGATAGCAAAT 354
iNOS CAAGAGTTTGACCAGAGGACC TGGAACCACTCGTACTTGGGA 450
IL-1β GGCAACTGTTCCTGAACTCAACTG CCATTGAGGTGGAGAGCTTTCAGC 447
IL-6 CCACTTCACAAGTCGGAGGCTT CCAGCTTATCTGTTAGGAGA 395
IL-10 GCCAGTACAGCCGGGAAGACAATA GCCTTGTAGACACCTTGGTCTT 409
MMP-3 ATTCAGTCCCTCTATGGA CTCCAGTATTTGTCCTCTAC 375
MMP-8 CCAAGGAGTGTCCAAGCCAT CCTGCAGGAAAACTGCATCG 180
MMP-9 GTGATCCCCACTTACTATGGAAAC GAAGCCATACAGTTTATCCTGGTC 352
TIMP-2 TCTAATTGCAGGAAAGGCAGA TGCTCTTCTCTGTGACCCAGT 218
HO-1 TGTCACCCTGTGCTTGACCT ATACCCGCTACCTGGGTGAC 209
NQO1 AGAGGCTCTGAAGAAGAGAGG CACCCTGAAGAGAGTACATGG 401
p47phox CGATGGATTGTCCTTTGTGC ATCACCGGCTATTTCCCATC 256
p67phox CTTCAACATAGGCTGCGTGA CTTCATGTTGGTTGCCAATG 334
p22phox AAAGAGGAAAAAGGGGTCCA TAGGCTCAATGGGAGTCCAC 239
gp91phox GTCAAGTGCCCCAAGGTATCCA TTGTAGCTGAGGAAGTTGGC 453
GAPDH ATGTACGTAGCCATCCAGGC AGGAAGGAAGGCTGGAAGAG 420
Rat TNF-α AAGTTCCCAAATGGGCTCCCT TGAAGTGGCAAATCGGCTGAC 306
iNOS GCAGAATGTGACCATCATGG ACAACCTTGGTGTTGAAGGC 426
IL-1β AAATGCCTCGTGCTGTCTGACC TCCCGACCATTGCTGTTTCCT 377
IL-6 TCATTCTGTCTCGAGCCCAC GAAGTAGGGAAGGCAGTGGC 345
IL-10 AGGGCTGCCTTCAGTCAAGT AGAAATCGATGACAGCGTCG 396
MMP-3 GTACCAACCTATTCCTGGTTGC CCAGAGAGTTAGATTTGGTGGG 231
MMP-8 TACAACCTGTTTCTCGTGGCTGC TCAACTGTTCTCAGCTGGGGATG 317
MMP-9 AAGTTGAACTCAGCCTTTGAGG GTCGAATTTCCAGATACGTTCC 225
TIMP-2 CGTAGTGATCAGAGCCAAGC TCTGCCTTTCCTGCAATTAGA 225
GAPDH GTGCTGAGTATGTCGTGGAGTCT ACAGTCTTCTGAGTGGCAGTGA 292
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BV2 cells plated at 50–60 % confluence (2 × 105 cells
per well) in 12-well plates were transfected with 1 μg
of plasmid DNA (ARE-luc, CRE-luc) using the Con-
voy™ Platinum transfection reagent (CellTAGen,
Seoul, Korea). After 36 h of transfection, cells were
treated with β-LAP and LPS (100 ng/ml), or β-LAP
only, for 6 h. The luciferase assay was used to deter-
mine the effect of β-LAP on ARE or CRE promoter
activity. The ARE-luciferase reporter gene was kindly
provided by Dr. Young-Joon Surh (Seoul National
University, Seoul, Korea). The sequence of the anti-
oxidant response element (ARE) construct is as fol-
lows: 5′-CTCAGCCTTCCAAATCG CAGTCACAGT
GACTCAGCAGAATC-3′ [27, 28]. The CRE-luc vec-
tor, which contains four copies of the cyclic AMP re-
sponse element (CRE, TGACGTCA), was obtained
from Stratagene (La Jolla, CA).EMSA
Nuclear extracts from treated microglia were prepared as
follows. Cells (2 × 107) were treated with 1 ml of lysis buffer
(10 mM Tris–HCl, pH 7.9; 10 mM NaCl; 3 mM MgCl2;
1 % NP-40) on ice for 5 min. After 10 min of centrifugation
at 3000 rpm, the pellet was resuspended in 50 μl of extrac-
tion buffer (20 mM HEPES, pH 7.9; 20 % glycerol; 1.5 mM
MgCl2; 0.2 mM EDTA; 300 mM NaCl; 1 mM DTT; 1 mM
PMSF) and incubated on ice for 30 min. After centrifuga-
tion at 13,200 rpm for 15 min, the supernatant was har-
vested as a nuclear protein extract and stored at −70 °C.
Double-stranded DNA oligonucleotides containing the
NF-κB, AP-1, ARE, or CRE consensus sequences were end
labeled using T4 polynucleotide kinase (New England Bio-
labs, Beverly, MA) in the presence of [γ-32P]ATP. Nuclear
proteins (5 μg) were incubated with 32P-labeled probe on
ice for 30 min, resolved on a 5 % acrylamide gel, and visu-
alized by autoradiography. We purchased double-stranded
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CRE consensus sequences from Promega (Madison, WI,
USA) and that containing ARE from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). The DNA sequences of the
probes are as follows: NF-κB (5′-AGTTGAGGGGAC
TTTCCCAGGC-3′), AP-1 (5′-CGCTTGATGAGTCAGC
CGGAA-3′), ARE (5′-TGG GGAACCTGTGCTGAGTC
ACTGGAG-3′), and CRE (5′-AGAGATTGCCTGACG
TCAGAGAGCTA-3′).
Statistical analysis
Unless otherwise stated, all experiments were per-
formed with triplicate samples and repeated at least
three times. Data are presented as mean ± SEM, and
statistical comparisons among groups were performed
using one-way ANOVA followed by Newman–Keuls
post hoc tests or t tests. Statistical significance was ac-
cepted for P values <0.05.
Results
β-LAP showed anti-inflammatory effects in LPS-stimulated
microglial cells
To investigate the anti-inflammatory effect of β-LAP,
BV2 or primary microglial cells were treated with LPS in
the presence or absence of β-LAP for 16 h. Consecu-
tively, NO and cytokine levels in CM were measured.
We observed that β-LAP significantly inhibited the LPS-
induced production of NO and proinflammatory cyto-
kines such as TNF-α, IL-1β, and IL-6, whereas it raised
anti-inflammatory IL-10 in BV2 cells and primary
microglia (Fig. 1a, b). β-LAP did not have any cytotox-
icity in the concentrations used in this study in both the
BV2 and primary microglial cells, at least for 48 h (MTT
assay, data not shown). Subsequent RT-PCR analysis
showed that β-LAP reduced the mRNA expression of
iNOS, TNF-α, IL-1β, and IL-6, and increased IL-10
(Fig. 1c, d). The data suggest that β-LAP modulates the
expressions of iNOS and cytokines at the transcriptional
level.
β-LAP suppressed the expression and activity of MMP-3,
MMP-8, and MMP-9, while it enhanced TIMP-2 expression
in LPS-stimulated microglia
Our group recently reported that MMP-3, MMP-8, and
MMP-9 are important proinflammatory mediators in
activated microglia, while TIMP-2 plays an anti-
inflammatory role [21–23, 29]. To investigate whether
β-LAP affects the expression of MMPs and TIMP-2, we
performed RT-PCR analysis and Western blotting using
cell lysates and CM from LPS + β-LAP-treated micro-
glial cells. We found that β-LAP inhibited LPS-induced
expressions of MMP-3, MMP-8, and MMP-9 at the
mRNA and protein levels in both BV2 cells and pri-
mary microglia (Fig. 2a, b). Moreover, β-LAP reducedthe enzymatic activity of MMP-3, MMP-8, and MMP-9
in the CM (Fig. 2d). On the other hand, β-LAP restored
the expression of TIMP-2 (Fig. 2a–c). The results sug-
gest that the inhibition of MMPs and the upregulation
of TIMP-2 are at least partly involved in the anti-
inflammatory effects of β-LAP.β-LAP inhibited microglial activation and the expression
of iNOS, cytokines, and MMPs in the brains of LPS-
induced systemic inflammation mice
To verify the anti-inflammatory effects of β-LAP in vivo,
β-LAP (10 mg/kg) was injected before LPS administration.
After 3 h, microglial activation and the expression levels
of proinflammatory cytokines and MMPs were measured
in the LPS-injected mouse brain. Systemic LPS led to an
increase in densely stained Iba1-positive cells in the cortex
and dentate gyrus (Fig. 3a). This indicates the presence of
activated microglia. Pretreatment of β-LAP, however, re-
duced their number. The smaller amount of densely
stained activated microglia was significant as seen in the
subsequent quantification of Iba1-positive cells. However,
we did not observe any infiltration of neutrophils or
monocytes into the brain at this time point (i.e., 3 h) (data
not shown). In addition, we found that β-LAP inhibited
the mRNA expression of proinflammatory cytokines
(IL-6, IL-lβ, TNF-α), iNOS, and MMPs (MMP-3, MMP-8,
MMP-9) that were elevated in the cortex region of the
LPS-injected mouse brain (Fig. 3b, c). To determine
whether MMPs, upregulated in the cortex of LPS-injected
mouse, were co-localized with microglia, immunohisto-
chemistry was performed using antibodies against Iba1
(red) and MMP-3, MMP-8, or MMP-9 (green), 24 h after
the LPS challenge. The number of double-immunopositive
cells was significantly increased by LPS injection, but it was
reduced in the β-LAP-injected groups (Fig. 4). The results
indicate that β-LAP inhibits the expression of MMP-3,
MMP-8, and MMP-9 in the microglia of the LPS-injected
mouse brain.β-LAP inhibited the phosphorylation of MAPKs and AKT
and the DNA binding activity of NF-κB and AP-1 in LPS-
stimulated BV2 cells
To further investigate the anti-inflammatory mechanism
of β-LAP, we examined the effects of β-LAP on MAPKs
and PI3K/AKT signaling, which play a critical role in the
process of microglial activation and the production of NO
and cytokines [30, 31]. We found that β-LAP significantly
inhibited the phosphorylation of three types of MAPKs
and AKT in LPS-stimulated BV2 cells (Fig. 5a, b). Further-
more, we found that β-LAP suppressed the DNA binding
activity of NF-κB and AP-1, which are key transcription
factors modulating cytokine and iNOS gene expression in
microglia (Fig. 5c, d).
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Fig. 1 Effects of β-LAP on iNOS and pro-/anti-inflammatory cytokines in LPS-stimulated BV2 cells and primary cultured microglia. BV2 cells (a) or
primary cultured microglia (b) were pretreated with β-LAP (0.5, 1, and 2 μM) for 1 h and incubated with LPS (100 ng/ml for BV2, 10 ng/ml for
primary microglia). After incubation for 16 h, the conditioned media were collected, and the amounts of NO, TNF-α, IL-1β, IL-6, and IL-10 were
measured using Griess reagent or ELISA. The data are the mean ± SEM of three independent experiments. *P < 0.05, significantly different from
LPS-treated samples. BV2 cells (c) or primary microglia (d) were pretreated with β-LAP (0.5, 1, and 2 μM) for 1 h, followed by LPS (100 ng/ml) for
6 h, and total RNA was isolated. The mRNA expressions of iNOS and cytokines were analyzed by RT-PCR. Representative gels are shown on the left
panel, and quantifications of three independent experiments are shown in the right panel. Values correspond to the mean ± SEM of three
independent experiments. *P < 0.05, significantly different from LPS-treated samples
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NADPH oxidase subunits, whereas it enhanced anti-
oxidant enzyme HO-1/NQO1 expression
Next, we examined the effects of β-LAP on LPS-induced
ROS production, which acts as a second messenger in
inflammatory reactions and subsequent neuronal cell
death [32, 33]. β-LAP significantly inhibited LPS-
induced ROS production in the BV2 cells and primary
microglia (Fig. 6a–c). Since NADPH oxidase is a major
enzyme for microglial ROS release, we examined the ef-
fect of β-LAP on membrane (gp91phox, p22phox) and
cytosolic (p47phox, p67phox) components of NADPH
oxidase. β-LAP suppressed the expression and phos-
phorylation of p47phox (Fig. 6d, e). Moreover, β-LAPinhibited the mRNA expression of gp91phox, without af-
fecting p67phox or p22phox (Fig. 6d). We next examined
the effects of β-LAP on HO-1 and NQO1, which medi-
ate anti-inflammatory and anti-oxidant effects in the ac-
tivated microglia [33, 34]. We observed that β-LAP
increased LPS-induced HO-1 and NQO1 expression at
mRNA and protein levels (Fig. 7a, b). Interestingly, we
found that β-LAP itself also increased HO-1 and NQO1
expression.
β-LAP activated Nrf2/ARE and PKA/CREB pathways
Because Nrf2 binds to ARE on the promoters of phase II
anti-oxidant enzyme genes such as HO-1 and NQO1,
and controls their expression [27, 34], we examined the
Fig. 2 β-LAP suppressed the LPS-induced expression and enzymatic activity of MMP-3, MMP-8, and MMP-9, whereas it enhanced TIMP-2
expression. BV2 cells (a) or primary microglia (b) were pretreated with β-LAP (0.5, 1, and 2 μM, for 1 h), followed by LPS (100 or 10 ng/ml), and
total RNA was isolated at 6 h after LPS treatments. The mRNA expressions of MMPs and TIMP-2 were analyzed by RT-PCR. Representative gels are
shown in the left panel, and quantification data are shown in the right panel (n = 3). c Western blot analysis was performed using conditioned
medium (CM) or cell lysates of BV2 cells pretreated with β-LAP (0.5, 1, and 2 μM, for 1 h), followed by LPS (100 ng/ml) for 16 h. Levels of MMP-3,
MMP-8, and MMP-9, and TIMP-2 protein expression were normalized using β-actin and were expressed as relative fold changes in comparison
with control samples. d The enzymatic activities of MMPs in the CM were detected using MMP activity assay kits. BV2 cells were pretreated with
β-LAP (0.5, 1, and 2 μM, for 1 h), followed by LPS (100 ng/ml, for 24 h), and the CM was collected to measure MMP activity. MMP activity units
were expressed as a change in fluorescence intensity. Values are expressed as the means ± SEM for three independent experiments. *P < 0.05,
significantly different from the LPS-treated group
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1/NQO1 promoters. We observed that LPS induced
Nrf2 binding to ARE, which was enhanced by β-LAP
(Fig. 7c). Moreover, β-LAP increased ARE-driven lucifer-
ase activity in the absence and presence of LPS (Fig. 7d).
Previous studies of our own and by other groups re-
ported that the PKA/CREB pathway contributes to the
resolution of inflammation and ROS detoxification, and
that PKA is an upstream modulator of HO-1 expressionin microglia [35, 36]. In the present study, we observed
that β-LAP itself increased the phosphorylation of CREB,
which is a downstream target of PKA. In addition, β-LAP
potentiated the CREB phosphorylation induced by LPS
(Fig. 7e). β-LAP also increased the DNA binding and
transcriptional activity of CREB in the absence or presence
of LPS (Fig. 7f, g). Thus, the data suggest that the Nrf2/
ARE and PKA pathways are largely involved in the anti-
inflammatory/anti-oxidant mechanism of β-LAP, in
Fig. 3 (See legend on next page.)
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Fig. 3 β-LAP reduced neuroinflammation induced by systemic LPS administration. a Immunofluorescence labeling of Iba1 (red) and quantification of
the number of activated Iba1-positive cells 3 h after systemic LPS treatment (5 mg/kg, i.p.). Nuclei are counterstained with DAPI (blue). Microglial
activation in the cortex and dentate gyrus (DG) of LPS-injected mouse was reduced by β-LAP (10 mg/kg, i.p., daily for 4 days) treatment. Representative
images were obtained from one set of experiments, and the three experiments were performed independently. Upper images are the results of Iba1 +
DAPI staining with an original magnification of ×40. Lower images are the results of Iba1 staining with an original magnification of ×400. b, c β-LAP
reduced the mRNA expression of proinflammatory cytokines (IL-6, IL-1β, TNF-α), iNOS, and MMPs (MMP-3, MMP-8, and MMP-9) in the cortex of LPS-
injected mice (5 mg/kg, 3 h). Representative gels are shown in the left panel, and quantification data are shown in the right panel (n = 3 in each group).
Results are representative RT-PCR data in the cortex 3 h after LPS treatment. Values are expressed as the means ± SEM for three independent
experiments. *P < 0.05 vs. saline or #P < 0.005 vs. LPS-treated mice
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and PI3K/AKT.
Discussion
Our present study demonstrates the anti-inflammatory
properties of β-LAP in brain microglia and their under-
lying molecular mechanisms. β-LAP inhibited the ex-
pressions of iNOS and proinflammatory cytokines in
LPS-stimulated microglia. In addition, β-LAP reduced
the expression and activity of MMP-3, MMP-8, and
MMP-9, which are inflammatory mediators in activated
microglia [21–23]. By using a systemic inflammation
mouse model, we confirmed the anti-inflammatory role
of β-LAP. Thus, β-LAP inhibited microglial activation
and the expression of proinflammatory molecules in the
LPS-injected mouse brain. By mechanistic analysis, we
showed that β-LAP inhibited the phosphorylation of
MAPKs and AKT and the DNA binding activity of NF-
κB/AP-1 induced by LPS. Furthermore, we found that β-
LAP exerts anti-oxidant effects by reducing ROS
production via suppression of NADPH oxidase subunit
activity and/or expression, and upregulation of anti-
oxidant enzymes such as HO-1 and NQO1. We showed
that β-LAP activated Nrf2/ARE and PKA/CREB path-
ways, which are involved in the upregulation of HO-1/
NQO1 expression. Therefore, β-LAP appears to act as
an anti-inflammatory/anti-oxidant agent by modulating
multiple signaling pathways (i.e., inhibition of MAPKs
and PI3K/AKT, upregulation of Nrf2/ARE and PKA).
A previous study reported that β-LAP inhibits the
mRNA expression of TLR4 signaling molecules in ex-
perimental autoimmune encephalomyelitis mice [37]. In
the present study, however, β-LAP did not affect the
mRNA expression of TLR4 or MyD88 in LPS-stimulated
microglia (Additional file 1: Figure S1), suggesting that
β-LAP exerts anti-inflammatory effects by modulating
signaling downstream of TLR4/MyD88 and/or via a
MyD88-independent pathway. In addition, we found that
β-LAP also inhibited the inflammatory reactions induced
by TLR2 or TLR3 agonists. Treatment with β-LAP
inhibited NO and TNF-α production in BV2 cells stimu-
lated with lipoteichoic acid (LTA; TLR2 agonist) or poly-
inosinic–polycytidylic acid (Poly I:C; TLR3 agonist)
(Additional file 1: Figure S2). Thus, the data imply thatthe anti-inflammatory effect of β-LAP is not confined to
TLR4 activation. Further studies are necessary to investi-
gate the detailed mechanism underlying the effect of β-
LAP on TLR signaling.
MMPs are zinc-dependent endopeptidases which are in-
volved not only in normal brain development but also in
various neuropathological conditions such as Alzheimer’s
disease, Parkinson’s disease, stroke, and multiple sclerosis
[38]. MMPs are aberrantly expressed in neuropathological
conditions and cause breakdown of the blood–brain bar-
rier (BBB), infiltration of peripheral immune cells, demye-
lination, and neuronal cell death [39, 40]. Our group
recently reported that MMPs play an important role in
various neuroinflammatory conditions [21–23]. We
showed that MMP-3, MMP-8, and MMP-9 are upregu-
lated in LPS or α-synuclein-stimulated microglia and me-
diate neuroinflammatory reactions. Thus, the specific
inhibition of MMP-3, MMP-8, or MMP-9 suppresses
iNOS and cytokine expressions in LPS or α-synuclein-
stimulated microglia. We demonstrated that MMPs cleave
the N-terminal extracellular domain of protease-activated
receptor-1 and activate intracellular inflammatory signal-
ing pathways in α-synuclein-activated microglia [21].
More recently, we showed that MMP-8 plays a pivotal role
in neuroinflammation by activating TNF-α processing in
microglia [22]. We also reported that TIMP-2, as an en-
dogenous inhibitor of MMPs, has an anti-inflammatory
effect by modulating MMP-3, MMP-8, and MMP-9 in ac-
tivated microglia [29]. Based on these findings, our
present study examined the effects of β-LAP on MMPs
and TIMP-2 in LPS-stimulated microglia. We observed
that β-LAP significantly suppressed the expression and ac-
tivity of MMP-3, MMP-8, and MMP-9 with enhancement
of TIMP-2 under in vitro and/or in vivo neuroinflamma-
tory conditions, which may contribute to the anti-
inflammatory properties of β-LAP.
In this study, we found that β-LAP induced phase II
anti-oxidant enzymes such as HO-1 and NQO1, which
are regulated through the Nrf2/ARE signaling pathway
[34]. Under normal conditions, Nrf2 is sequestered by
cytosolic Keap1, which serves as an adaptor to link Nrf2
to the ubiquitin ligase Cul3–Rbx1 complex that ubiquiti-
nates and degrades Nrf2. However, upon stimulation by
electrophilic agents or ROS, Nrf2 dissociates from its
Fig. 4 β-LAP suppressed MMP-3, MMP-8, and MMP-9 expression in the LPS-induced systemic inflammation mouse brain. Changes in protein
expression of MMP-3 (a), MMP-8 (b), and MMP-9 (c) were determined in LPS (24 h)-injected mouse brains. The number of activated Iba1+
cells with thick and densely stained processes was markedly increased in the cortex at 24 h after systemic LPS treatment (5 mg/kg, i.p.),
compared to saline groups. MMP-3, MMP-8, and MMP-9 expression in the cortex of LPS-injected mouse was reduced by treatment with
β-LAP (10 mg/kg, i.p., daily for 4 days). Representative images of MMP-positive cells and double-positive cells (MMP, green; Iba-1, red), as
determined by immunohistochemistry. Representative images (a–c) and quantification of the data (d). Values represent the number of
double-immunopositive cells. Scale bar, 100 μm. n = 3 per group. *P < 0.05 vs. saline or #P < 0.005 vs. LPS-treated mice
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nucleus, and binds to the ARE site [41]. It has been sug-
gested that Nrf2 phosphorylation is involved in this
release process. In the present study, we observed that
β-LAP increased Nrf2 binding to ARE, as well as ARE-
mediated transcriptional activity. However, we did not
further examine the effect of β-LAP on the Nrf2 release
mechanism related to Keap1; this would be an interest-
ing study in the future.
It is well-known that β-LAP is a substrate and activa-
tor of NQO1, which catalyzes the oxidation of NADH to
NAD+. A recent study reported that β-LAP induces
HO-1 expression by increasing NQO1 activity and
AMPK phosphorylation in RAW264.7 macrophages
[18, 19]. As a mechanism to resolve the neurotoxic
responses brought about by microglial activation,
microglia usually express anti-inflammatory cytokines(i.e., IL-10, TGF-β1), suppressor of cytokine signaling
(SOCS)-family proteins (i.e., SOCS1 and SOCS3), and
anti-oxidant enzymes (i.e., HO-1, NQO1, SOD) [42, 43].
In the present study, we found that LPS itself increased
HO-1 expression, which is associated with ARE-
dependent transcription. We previously reported that
the activation of PKA/CREB signaling is upstream of
HO-1 expression and that the upregulation of the HO-1
and PKA pathway plays a key role in mediating the anti-
inflammatory mechanism in LPS-stimulated microglia
[35]. Therefore, the potentiation of HO-1/ARE and PKA/
CREB by β-LAP may at least partly contribute to the
anti-inflammatory and anti-oxidant effects of β-LAP in
LPS-stimulated microglia. Interestingly, a recent study
demonstrated that HO-1 knockout markedly increases
MMP-9 expression in arteriovenous fistulas in mice
and that MMP-9 induction reflects the prooxidant and
Fig. 5 β-LAP inhibited the phosphorylation of MAPKs and AKT and DNA binding of NF-κB and AP-1 in LPS-stimulated BV2 cells. a Western
blots for MAPKs and AKT activities. Cell extracts were prepared from BV2 cells pretreated with β-LAP (0.5, 1, and 2 μM, for 1 h), followed by
LPS (100 ng/ml, for 1 h), and then subjected to immunoblot analysis using antibodies against the phospho- or total forms of JNK, ERK, p38
MAPK, and Akt. The autoradiograms are representative of three independent experiments. b Quantification of Western blot data. Levels of the
phosphorylated forms of MAPKs and AKT were normalized with respect to the level of each total form and expressed as relative fold changes
vs. the control group. Data are the means ± SEM for three independent experiments. *P < 0.05, significantly different from the LPS-treated
samples. c, d EMSA for NF-κB and AP-1 DNA binding activity. BV2 cells were pretreated with β-LAP (0.5, 1, and 2 μM, for 1 h), followed by LPS
(100 ng/ml, for 3 h), and nuclear extracts prepared from BV2 cells were incubated with the NF-κB (c) or AP-1 (d) probes. The arrow indicates a
DNA–protein complex of NF-κB or AP-1. F indicates a free probe
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Fig. 6 β-LAP inhibited ROS production via suppression of NADPH oxidase subunits. a BV2 cells or b primary microglia were pretreated with β-
LAP (0.5, 1, and 2 μM, for 1 h), followed by LPS (100 or 10 ng/ml, for 16 h), and stained with 50 μM H2DCF-DA. DCF fluorescence intensities were
measured using a microplate fluorometer. The data are expressed as the means ± SEM of three independent experiments. *P < 0.05, significantly
different from the LPS-treated group. c A representative confocal image of DCF-derived fluorescence (green) in BV2 cells (n = 3), with an original
magnification of ×200. d RT-PCR analysis for NADPH oxidase subunits (p47phox, p67phox, gp91phox, p22phox). BV2 cells were pretreated with β-
LAP (0.5, 1, and 2 μM, for 1 h) followed by LPS (100 ng/ml), and total RNA was isolated at 2 h after LPS treatment. Representative gels are shown
in the left panel, and quantification data are shown in the right panel (n = 3). e Western blot analysis for phosphorylation of the p47phox subunit
(n = 3). BV2 cells were pretreated with β-LAP (0.5, 1, and 2 μM, for 1 h), followed by LPS (100 ng/ml, for 30 min), and then subjected to immunoblot
analysis using antibodies against phospho-p47phox. Quantification data are shown in the graph. *P < 0.05, significantly different from the
LPS-treated group
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ficiency [44]. Therefore, the upregulation of HO-1/NQO1
may at least partly contribute to the anti-inflammatory ef-
fects of β-LAP by suppressing proinflammatory molecules
such as cytokines and MMPs in LPS-stimulated microglia.
A number of studies have reported therapeutic and
health benefits of β-LAP supplementation in experimen-
tal animal models and clinical trials. The most exten-
sively studied property of β-LAP is its anti-cancer
potential, and β-LAP is currently being evaluated in clin-
ical trials for treatment of cancer [9, 11]. In addition, β-
LAP has beneficial effects on metabolic syndromes such
as obesity, diabetes, hypertension, arterial restenosis, and
salt-induced renal injury [45–48]. The anti-inflammatory/
cytoprotective effects of β-LAP have also been reported inseveral disease models. β-LAP attenuates cisplatin-
mediated acute kidney injury in mice by suppressing crit-
ical mediators for inflammation and ROS [15]. β-LAP has
shown therapeutic effects against rheumatoid arthritis by
inhibiting synoviocyte proliferation and suppressing MMP
expression in chondrocytes [49]. β-LAP also protects
against renal ischemia/reperfusion injury in mice by indu-
cing NQO1 activation and subsequent inhibition of ROS
[50]. In experimental autoimmune encephalomyelitis, an
animal model of multiple sclerosis, the administration of
β-LAP ameliorates the development of EAE by inhibiting
the production of IL-12 family cytokines [37]. Interest-
ingly, a recent study demonstrated that potentiation of
NQO1 activity by feeding β-LAP prevents the age-
dependent decline of motor and cognitive function in
Fig. 7 β-LAP increased HO-1 and NQO1 expression via upregulation of Nrf2/ARE and PKA/CREB pathways in LPS-stimulated microglia. a Western
blot analysis shows the effects of β-LAP on HO-1 and NQO1 protein expression. Cell lysates were obtained from BV2 cells treated with β-LAP
(0.5, 1, and 2 μM) with or without LPS (100 ng/ml) for HO-1 or NQO1 (6–16 h). b RT-PCR was performed to determine the HO-1 and NQO1 mRNA
expression. Cells were treated with β-LAP (0.5, 1, and 2 μM) for 1 h prior to treatment with LPS (100 ng/ml, for 6 h) and analyzed. Quantification
data are shown in the graph (n = 3). c EMSA for Nrf2. Nuclear extracts were prepared from BV2 cells treated with LPS (100 ng/ml, for 3 h) or
LPS + β-LAP (1 and 2 μM, pretreatment for 1 h) and incubated with the ARE probe. The arrow indicates a DNA–protein complex of Nrf2. d Effect
of β-LAP on ARE-luc reporter gene activity. Cells transfected with the reporter plasmid (ARE-luc) were treated with β-LAP (0.5, 1, and 2 μM) with
or without LPS (100 ng/ml) for 6 h, and the reporter gene assay was performed. e Effect of β-LAP on the phosphorylation of CREB. Cell lysates were
obtained from BV2 cells treated with β-LAP (0.5, 1, and 2 μM) with or without LPS (100 ng/ml) for 1 h. Quantification data are shown in the graph
(n = 3). f EMSA for CREB. Nuclear extracts were prepared from BV2 cells treated with LPS (100 ng/ml, for 3 h) or LPS + β-LAP (1 and 2 μM, pretreatment
for 1 h) and incubated with the CRE probe. The bracket indicates a DNA–protein complex of CREB. g Effect of β-LAP on CRE-luc activity. Cells
transfected with the reporter plasmid (CRE-luc) were treated with β-LAP (0.5, 1, and 2 μM), with or without LPS (100 ng/ml) for 6 h, and the reporter
gene assay was performed. Data are the means ± SEM of three independent experiments. *P < 0.05 vs. control or #P < 0.05 vs. the LPS-treated group
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ance and prevents the loss of synapses in aged mice,
suggesting the therapeutic potential of β-LAP for neuro-
degenerative diseases.As to the BBB permeability of β-LAP, Huntingdon Life
Sciences (UK) has reported that a minimal concentration
of β-LAP penetrates into the rat brain, compared with
other organs, under normal conditions (unpublished
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the mechanism of β-LAP: first, β-LAP suppresses the per-
ipheral inflammation induced by LPS and results in the in-
hibition of subsequent brain inflammation, and second, in
systemic inflammatory conditions, BBB permeability is
compromised and thus the penetration of β-LAP into the
brain might be enhanced. In the latter case, β-LAP may dir-
ectly modulate microglial activation. We believe that both
of these mechanisms may be simultaneously involved in β-
LAP action.
Conclusions
The present study demonstrates that β-LAP inhibits neu-
roinflammation by modulating various inflammatory mol-
ecules and multiple signaling pathways. Considering the
high demand for anti-inflammatory agents that can modu-
late microglial activation, β-LAP may be a promising pre-
ventive therapeutic agent against neuroinflammatory
disorders such as Alzheimer’s disease and Parkinson’s
disease.
Additional file
Additional file 1: Figures S1 and S2. Figure S1. Effects of β-lapachone
on TLR4 and MyD88 expression in LPS-stimulated BV2 cells and mouse
brain. (A) BV2 cells were pretreated with β-LAP (0.5, 1, and 2 μM) for 1 h,
followed by treatment with LPS (100 ng/ml) for 6 h. Subsequently, total
RNA was isolated and RT-PCR analysis was performed. (B) mRNA expression
levels in the mouse brain were measured by RT-PCR analysis after 3 h of LPS
injection. β-LAP (10 mg/kg, i.p.) was given daily for 4 days before LPS
treatment. Representative gels of RT-PCR analysis are shown on the top,
and quantifications of three independent experiments are shown in the
bottom panel. Values correspond to the mean ± SEM of three
independent experiments. Figure S2. Effects of β-lapachone on NO
and TNF-α production in LTA (TLR2 agonist) or Poly I:C (TLR3 agonist)-
stimulated BV2 microglial cells. Cells were incubated for 24 h with LTA
(10 μg/ml) or Poly I:C (25 μg/ml) in the absence or presence of β-
lapachone, and the amounts of NO and TNF-α were measured in the
supernatants. The bars indicate the mean ± SEM of three independent
experiments. *P < 0.05, significantly different from stimulant-treated
cells.
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